ALLMedicine™ Myelodysplastic Syndromes Center
Research & Reviews 6,241 results
https://doi.org/10.1038/s41375-021-01190-9 10.1002/cytob.21139 10.1002/cyto.b.21536 10.1111/j.0902-4441.2005.t01-1-EJH2467.x 10.1007/s00277-014-2267-x 10.1111/j.1365-2141.2009.07822.x 10.1182/blood-2002-12-3706 10.1182/blood-2005-06-2485 10.1182/blood-2002-03-0799 10.3324/haematol.2018.198846 10.1111/bjh.16427 10.5858/2005-129-96-ALLTIA 10.1111/bjh.12661 10.1007/s00277-015-2348-5 10.1111/j.1365-2141.2008.07450.x 10.1182/bloodadvances.2018019414 10.3389/fonc.2018.00587 10.1080/17474086.2017.1339597
Leukemia Fattizzo B, Ireland R et. al.
Mar 5th, 2021 - In this large single-centre study, we report high prevalence (25%) of, small (<10%) and very small (<1%), paroxysmal nocturnal hemoglobinuria (PNH) clones by high-sensitive cytometry among 3085 patients tested. Given PNH association with bone marr...
https://doi.org/10.1159/000513542
Annals of Nutrition & Metabolism; Kanehira D, Koinuma M et. al.
Mar 4th, 2021 - Predicting tolerability and treatment-related risks associated with azacitidine (AZA) in patients with myelodysplastic syndromes (MDS) before the initiation of therapy is required for appropriate treatment. Thus, in this study, the nutritional sta...
https://doi.org/10.1182/bloodadvances.2020003381
Blood Advances; Rozema J, Hoogendoorn M et. al.
Mar 3rd, 2021 - Population-based studies that contain detailed clinical data on patients with myelodysplastic syndrome (MDS) are scarce. This study focused on the real-world overall survival (OS) of MDS patients in association with comorbidities, specifically mal...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919086
Journal of Medical Case Reports; Sun Y, Blieden C et. al.
Mar 2nd, 2021 - Hemophagocytic lymphohistiocytosis (HLH) is characterized by hyperinflammation and life-threatening cytopenias. Survival is poor, and management is pivotal on rapid identification of the disease. HLH is associated with hematologic malignancies, ho...
https://doi.org/10.1136/jitc-2020-001818
Journal for Immunotherapy of Cancer; Saberian C, Abdel-Wahab N et. al.
Feb 27th, 2021 - Immune checkpoint inhibitors (ICIs) are being used after allogeneic hematopoietic stem cell transplantation (alloHCT) to reverse immune dysfunction. However, a major concern for the use of ICIs after alloHCT is the increased risk of graft-versus-h...
Guidelines 31 results
https://doi.org/10.1016/j.annonc.2020.11.002
Annals of Oncology : Official Journal of the European Soc... Fenaux P, Haase D et. al.
Nov 22nd, 2020 - Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†☆.|2020|Fenaux P,Haase D,Santini V,Sanz GF,Platzbecker U,|diagnosis,epidemiology,therapy,
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200129/full/
May 12th, 2020 - A substantial proportion of Medicare patients with myelodysplastic syndromes (MDS) do not undergo a complete diagnostic evaluation (CDE), including a bone marrow biopsy, to confirm their disease (Abstract 7555).
http://www.hematology.org/Clinicians/Guidelines-Quality/503.aspx
Allen, S.
Feb 20th, 2018 - These clinical performance measures are designed for individual quality improvement. Some of the measures may also be appropriate for accountability if appropriate sample sizes and implementation rules are achieved.
https://doi.org/10.6004/jnccn.2017.0007
Journal of the National Comprehensive Cancer Network : JN... Greenberg PL, Stone RM et. al.
Jan 3rd, 2017 - The myelodysplastic syndromes (MDS) comprise a heterogenous group of myeloid disorders with a highly variable disease course. Diagnostic criteria to better stratify patients with MDS continue to evolve, based on morphology, cytogenetics, and the p...
http://www.bloodjournal.org/content/122/17/2943
Malcovati, L.,et al.
Oct 23rd, 2013 - Within the myelodysplastic syndrome (MDS) work package of the European LeukemiaNet, an Expert Panel was selected according to the framework elements of the National Institutes of Health Consensus Development Program. A systematic review of the lit.
Drugs 57 results see all →
Clinicaltrials.gov 6,495 results
https://doi.org/10.1038/s41375-021-01190-9 10.1002/cytob.21139 10.1002/cyto.b.21536 10.1111/j.0902-4441.2005.t01-1-EJH2467.x 10.1007/s00277-014-2267-x 10.1111/j.1365-2141.2009.07822.x 10.1182/blood-2002-12-3706 10.1182/blood-2005-06-2485 10.1182/blood-2002-03-0799 10.3324/haematol.2018.198846 10.1111/bjh.16427 10.5858/2005-129-96-ALLTIA 10.1111/bjh.12661 10.1007/s00277-015-2348-5 10.1111/j.1365-2141.2008.07450.x 10.1182/bloodadvances.2018019414 10.3389/fonc.2018.00587 10.1080/17474086.2017.1339597
Leukemia Fattizzo B, Ireland R et. al.
Mar 5th, 2021 - In this large single-centre study, we report high prevalence (25%) of, small (<10%) and very small (<1%), paroxysmal nocturnal hemoglobinuria (PNH) clones by high-sensitive cytometry among 3085 patients tested. Given PNH association with bone marr...
https://doi.org/10.1159/000513542
Annals of Nutrition & Metabolism; Kanehira D, Koinuma M et. al.
Mar 4th, 2021 - Predicting tolerability and treatment-related risks associated with azacitidine (AZA) in patients with myelodysplastic syndromes (MDS) before the initiation of therapy is required for appropriate treatment. Thus, in this study, the nutritional sta...
https://doi.org/10.1182/bloodadvances.2020003381
Blood Advances; Rozema J, Hoogendoorn M et. al.
Mar 3rd, 2021 - Population-based studies that contain detailed clinical data on patients with myelodysplastic syndrome (MDS) are scarce. This study focused on the real-world overall survival (OS) of MDS patients in association with comorbidities, specifically mal...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7919086
Journal of Medical Case Reports; Sun Y, Blieden C et. al.
Mar 2nd, 2021 - Hemophagocytic lymphohistiocytosis (HLH) is characterized by hyperinflammation and life-threatening cytopenias. Survival is poor, and management is pivotal on rapid identification of the disease. HLH is associated with hematologic malignancies, ho...
https://doi.org/10.1136/jitc-2020-001818
Journal for Immunotherapy of Cancer; Saberian C, Abdel-Wahab N et. al.
Feb 27th, 2021 - Immune checkpoint inhibitors (ICIs) are being used after allogeneic hematopoietic stem cell transplantation (alloHCT) to reverse immune dysfunction. However, a major concern for the use of ICIs after alloHCT is the increased risk of graft-versus-h...
News 287 results
https://reference.medscape.com/viewarticle/944879
Feb 2nd, 2021 - Guidelines on the diagnosis and treatment of myelodysplastic syndromes were published in November 2020 by the European Society of Medical Oncology.[1] The diagnosis of myelodysplastic syndromes (MDS) is based on the blood count, the marrow aspirat...
https://www.medscape.com/viewarticle/933602
Jul 7th, 2020 - The Food and Drug Administration has approved Inqovi (decitabine and cedazuridine tablets, Astex Pharmaceuticals) to treat adults with myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML). The agency's action gives physicians ...
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200129/full/
May 12th, 2020 - A substantial proportion of Medicare patients with myelodysplastic syndromes (MDS) do not undergo a complete diagnostic evaluation (CDE), including a bone marrow biopsy, to confirm their disease (Abstract 7555).
https://www.medscape.com/viewarticle/928198
Apr 5th, 2020 - The US Food and Drug Administration (FDA) has approved luspatercept (Reblozyl, Bristol-Myers Squibb/Acceleron) for the treatment of anemia in patients with myelodysplastic syndromes (MDS). The green light represents the first treatment advancement...
https://www.medscape.com/viewarticle/923569
Jan 9th, 2020 - (Reuters Health) - Therapy every 3 weeks with the drug luspatercept dramatically reduced the need for blood transfusions in a subset of patients with lower-risk myelodysplastic syndromes (MDS), according to results from the MEDALIST study reported...